Show simple item record

dc.contributor.authorMangione, Carol M
dc.contributor.authorBarry, Michael J
dc.contributor.authorNicholson, Wanda K
dc.contributor.authorCabana, Michael
dc.contributor.authorCaughey, Aaron B
dc.contributor.authorChelmow, David
dc.contributor.authorCoker, Tumaini Rucker
dc.contributor.authorDavis, Esa M
dc.contributor.authorDonahue, Katrina E
dc.contributor.authorJaén, Carlos Roberto
dc.contributor.authorKubik, Martha
dc.contributor.authorLi, Li
dc.contributor.authorOgedegbe, Gbenga
dc.contributor.authorPbert, Lori
dc.contributor.authorRuiz, John M
dc.contributor.authorStevermer, James
dc.contributor.authorWong, John B
dc.date.accessioned2023-01-03T15:42:39Z
dc.date.available2023-01-03T15:42:39Z
dc.date.issued2022-11-01
dc.identifier.citationUS Preventive Services Task Force, Mangione CM, Barry MJ, Nicholson WK, Cabana M, Caughey AB, Chelmow D, Coker TR, Davis EM, Donahue KE, Jaén CR, Kubik M, Li L, Ogedegbe G, Pbert L, Ruiz JM, Stevermer J, Wong JB. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. JAMA. 2022 Nov 1;328(17):1740-1746. doi: 10.1001/jama.2022.18625. PMID: 36318127.en_US
dc.identifier.eissn1538-3598
dc.identifier.doi10.1001/jama.2022.18625en_US
dc.identifier.pmid36318127
dc.identifier.urihttp://hdl.handle.net/20.500.14038/51514
dc.description.abstractImportance: Menopause is defined as the cessation of a person's menstrual cycle. It is defined retrospectively, 12 months after the final menstrual period. Perimenopause, or the menopausal transition, is the few-year time period preceding a person's final menstrual period and is characterized by increasing menstrual cycle length variability and periods of amenorrhea, and often symptoms such as vasomotor dysfunction. The prevalence and incidence of most chronic diseases (eg, cardiovascular disease, cancer, osteoporosis, and fracture) increase with age, and US persons who reach menopause are expected on average to live more than another 30 years. Objective: To update its 2017 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of systemic (ie, oral or transdermal) hormone therapy for the prevention of chronic conditions in postmenopausal persons and whether outcomes vary by age or by timing of intervention after menopause. Population: Asymptomatic postmenopausal persons who are considering hormone therapy for the primary prevention of chronic medical conditions. Evidence assessment: The USPSTF concludes with moderate certainty that the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal persons with an intact uterus has no net benefit. The USPSTF concludes with moderate certainty that the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal persons who have had a hysterectomy has no net benefit. Recommendation: The USPSTF recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal persons. (D recommendation) The USPSTF recommends against the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal persons who have had a hysterectomy. (D recommendation).en_US
dc.language.isoenen_US
dc.relation.ispartofJAMAen_US
dc.relation.urlhttps://doi.org/10.1001/jama.2022.18625en_US
dc.titleHormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statementen_US
dc.typeJournal Articleen_US
dc.source.journaltitleJAMA
dc.source.volume328
dc.source.issue17
dc.source.beginpage1740
dc.source.endpage1746
dc.source.countryUnited States
dc.identifier.journalJAMA
dc.contributor.departmentPopulation and Quantitative Health Sciencesen_US
dc.contributor.departmentPrevention Research Centeren_US


This item appears in the following Collection(s)

Show simple item record